Purpose To investigate the changes in choroidal thickness (CT), axial length (AL), and ocular perfusion pressure (OPP) accompanying intraocular pressure (IOP) reduction after trabeculectomy. Methods Thirty-nine eyes of 39 patients with primary open-angle glaucoma uncontrolled by medical therapy were included in this prospective and interventional study. All patients underwent a fornix-based trabeculectomy. The CT was measured by enhanced depth imaging-optical coherence tomography. IOP, AL, and systolic/ diastolic blood pressure were also measured, and OPP was calculated. All measurements were performed at baseline and 1 month after surgery. Results The mean IOP was 25.0 ± 5.8 mm Hg at baseline and 11.7 ± 2.6 mm Hg after trabeculectomy (Po0.001), and the mean subfoveal CT was 295±84 mm Hg at baseline and 331±82 mm Hg after trabeculectomy (Po0.001). The mean AL was 23.64 ± 0.98 mm at baseline and 23.54 ± 0.96 mm after trabeculectomy (Po0.001), whereas the mean OPP was 38.8 ± 6.2 mm Hg preoperatively, and 51.1 ± 7.3 mm Hg postoperatively (Po0.001). The change in CT negatively correlated with the change in IOP (r ¼ À 0.785, Po0.001) and AL (r ¼ À 0.693, Po0.001), whereas it positively correlated with the change in OPP (r ¼ 0.418, P ¼ 0.008). Conclusion These results suggest that the large IOP decrease following trabeculectomy causes choroidal thickening.In addition, CT changes are associated with IOP and AL reduction as well as OPP increase.
The CH, CRF, and Goldman-correlated IOP were significantly lower in the Marfan syndrome eyes with ectopia lentis than in the Marfan syndrome eyes without ectopia lentis.
Objective: We aimed to compare intraocular pressure (IOP) measurements via three different tonometers: the Goldmann applanation tonometer (GAT), the Tono-Pen ® XL (TPXL), and a non-contact airpuff tonometer (NCT).Methods: This was a cross-sectional study of 200 eyes from 200 patients. Right eyes of all patients were included in this study. IOP was measured via GAT, NCT, and TPXL by three physicians. Each physician used one of the tonometers. Measurements via the three devices were compared. Results: The mean IOP was 15.5±2.2 mmHg (range 10-22) with the GAT, 16.1±3.0 (range 9-25) with the TPXL, and 16.1±2.8 (range 10-26) with the NCT. Bland-Altman analysis showed that the mean difference between measurements from the NCT and the GAT was 0.6±2.3 mmHg. The mean difference between the TPXL and GAT measurements was 0.7±2.5 mmHg. The mean difference between the NCT and TPXL measurements was -0.02±3.0 mmHg. There was no significant difference between the groups according to a one-way analysis of variance (ANOVA) test. P-values were 0.998 for NCT-TPXL, 0.067 for NCT-GAT, and 0.059 for TPXL-GAT. Conclusion:The NCT and TPXL provide IOP measurements comparable to those of the gold standard GAT in normotensive eyes.
Pupose: The purpose of this study was to compare the biomechanical properties of the cornea and intraocular pressure (IOP) between patients with systemic lupus erythematosis (SLE) and age-matched controls. Patients and Methods: In this prospective study, 30 healthy individuals (control group) and 30 patients with SLE (study group) underwent Reichert ocular response analyzer (ORA) measurements. In the right eye of each participant, the corneal hysteresis (CH), corneal resistance factor (CRF), and Goldman-related IOP (IOPg) were recorded using the ORA. Results: Mean CH, CRF, IOPg were significantly different between groups. Mean CH was 10.2±0.6 mm Hg in the study group and 11.3±1.3 in the control group (P ¼ 0.02); mean CRF was 9.7±1.1 mm Hg and 11.9 ± 1.5 mm Hg, respectively (P ¼ 0.001). Mean IOP g was 13.9 ± 2.9 mm Hg in the study group and 16.9 ± 2.6 mm Hg in the control group (P ¼ 0.001). Conclusion: The biomechanical properties of the cornea are altered in patients with SLE compared with normal controls. These findings should be taken into account when measuring IOP values in patients with SLE as IOP readings may be underestimated in SLE eyes.
Objectives:To evaluate the efficacy of intravitreal bevacizumab (IVB) in the resolution of vitreous hemorrhage (VH) secondary to proliferative diabetic retinopathy (PDR).Materials and Methods:Seventy eyes of 70 patients (43 male, mean age 55.6±12.2 years) diagnosed with VH secondary to PDR were evaluated retrospectively. Demographic characteristics of the patients, baseline and final clinical results, and the interventions the patients were subject to were recorded. The patients who received IVB injections (group 1, n=29) were compared to those who did not receive injections (group 2, n=41) in terms of VH clearance time and surgery rates.Results:The mean follow-up time was 14.5±6.1 months in group 1 and 18.4±9.6 months in group 2 (p=0.185). The mean visual acuity was similar between the groups at baseline and at the last visit (for all p>0.05). Panretinal photocoagulation could be applied in 86% of subjects in group 1 and in 58% in group 2 2 within the first month (p=0.016). VH clearance time was not different between the groups (2.3±2.1 months in group 1 and 3.4±2.6 months in group 2, p=0.146). The number of subjects requiring surgery was 7 (24%) in group 1 and 20 (48.8%) in group 2 (p=0.048).Conclusion:IVB was found effective in cases with VH secondary to PDR in terms of reducing the need for surgery and increasing the rate of subjects to whom panretinal photocoagulation could be applied in the early period, although there was no impact on final visual acuity.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.